JP2024170482A5 - - Google Patents

Info

Publication number
JP2024170482A5
JP2024170482A5 JP2024150452A JP2024150452A JP2024170482A5 JP 2024170482 A5 JP2024170482 A5 JP 2024170482A5 JP 2024150452 A JP2024150452 A JP 2024150452A JP 2024150452 A JP2024150452 A JP 2024150452A JP 2024170482 A5 JP2024170482 A5 JP 2024170482A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
poloxamer
formulation according
seq
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024150452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024170482A (ja
Filing date
Publication date
Priority claimed from JP2023504043A external-priority patent/JP7367262B1/ja
Application filed filed Critical
Publication of JP2024170482A publication Critical patent/JP2024170482A/ja
Publication of JP2024170482A5 publication Critical patent/JP2024170482A5/ja
Pending legal-status Critical Current

Links

JP2024150452A 2021-12-01 2024-09-02 抗体含有製剤の調製方法 Pending JP2024170482A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021195788 2021-12-01
JP2021195788 2021-12-01
JP2023504043A JP7367262B1 (ja) 2021-12-01 2022-12-01 抗体含有製剤の調製方法
PCT/JP2022/044355 WO2023100975A1 (ja) 2021-12-01 2022-12-01 抗体含有製剤の調製方法
JP2023176016A JP7550286B2 (ja) 2021-12-01 2023-10-11 抗体含有製剤の調製方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023176016A Division JP7550286B2 (ja) 2021-12-01 2023-10-11 抗体含有製剤の調製方法

Publications (2)

Publication Number Publication Date
JP2024170482A JP2024170482A (ja) 2024-12-10
JP2024170482A5 true JP2024170482A5 (https=) 2025-12-09

Family

ID=86612242

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023504043A Active JP7367262B1 (ja) 2021-12-01 2022-12-01 抗体含有製剤の調製方法
JP2023176016A Active JP7550286B2 (ja) 2021-12-01 2023-10-11 抗体含有製剤の調製方法
JP2024150452A Pending JP2024170482A (ja) 2021-12-01 2024-09-02 抗体含有製剤の調製方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2023504043A Active JP7367262B1 (ja) 2021-12-01 2022-12-01 抗体含有製剤の調製方法
JP2023176016A Active JP7550286B2 (ja) 2021-12-01 2023-10-11 抗体含有製剤の調製方法

Country Status (11)

Country Link
US (2) US12460015B2 (https=)
EP (1) EP4442274A4 (https=)
JP (3) JP7367262B1 (https=)
KR (1) KR20240011866A (https=)
CN (1) CN118414166A (https=)
AU (1) AU2022399314A1 (https=)
CA (1) CA3239389A1 (https=)
IL (1) IL313202A (https=)
MX (1) MX2024006387A (https=)
TW (1) TW202333787A (https=)
WO (1) WO2023100975A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024380406A1 (en) * 2023-11-15 2026-04-16 Biotest Ag Method of manufacturing an igm containing composition

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ATE547161T1 (de) 2005-09-14 2012-03-15 Ares Trading Sa Verfahren zur quantitativen bestimmung von poloxameren
EP1951395B1 (en) 2005-09-14 2012-02-29 Ares Trading S.A. Method for the quantitative determination of poloxamers
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
KR101343040B1 (ko) 2010-12-28 2013-12-18 주식회사 삼양바이오팜 정제된 폴록사머 및 그의 정제방법
PL3160552T3 (pl) 2014-06-30 2020-03-31 Syqe Medical Ltd. Wkład z dawką leku dla urządzenia inhalacyjnego
KR102482733B1 (ko) 2014-06-30 2022-12-29 사이키 메디컬 엘티디. 유동 조절 흡입기 디바이스
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
EP3430072B1 (en) 2016-03-17 2020-07-01 Merck Patent GmbH Method for purifying poloxamers
MA44780A (fr) * 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
AU2021278562A1 (en) * 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Similar Documents

Publication Publication Date Title
JP2024170482A5 (https=)
Garau et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
JP2005538191A5 (https=)
Walling et al. Disseminated infection with Trichosporon beigelii
IL278528B2 (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
Hoffman et al. Fatal necrotizing esophagitis due to Penicillium chrysogenum in a patient with acquired immunodeficiency syndrome
Lorf et al. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome®) after liver transplantation
Markowitz Changing epidemiology of group A streptococcal infections
Bar-Joseph et al. Clostridium septicum infection in children with cyclic neutropenia
US20180303861A1 (en) Treating and preventing kidney damage
ES2334961B1 (es) Empleo de lauril galato en la prevencion y tratamiento de infeccionescausadas por el virus de la peste porcina africana (vppa).
CN1191061C (zh) 药用组合物
JP2024059762A5 (https=)
OA11287A (en) Method of enhancing bioavailability of fexofenadine and its derivatives.
MARTÍNEZ-ROIG et al. Double blind study of ketoconazole and griseofulvin in dermatophytoses
EP3220923B1 (en) Copolymer and method for treatment of bacterial infection
ES2867453T3 (es) Agente antiviral para el tratamiento de infecciones virales
Ortega Protozoan parasites
US4978687A (en) Anti-viral agent
JP7644128B2 (ja) 生物活性コポリマーの調製のためのプロセス
CN110859860A (zh) 一种可用于预防和/或治疗沙门氏菌感染的产品
JP7116428B2 (ja) 感染症治療薬
Klastersky Prevention and therapy of fungal infections in cancer patients: a review of recently published information
Turhan et al. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy
Flattery et al. New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents